Aptorum Group Announces Collaboration Between DiamiR And AlzLabs Precision Diagnostics To Generate Protein And MicroRNA Blood-Based Biomarker Data With Focus On Alzheimer's Disease

8-K filing — Niki BioSolutions, Inc. (APM)

Filed: 2026-07-20 AccNo: 0001213900-26-079416 Size: 751 KB Item 2.01: Completion of Acquisition or Disposition of Assets Item 3.03: Material Modifications to Rights of Security Holders Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Aptorum Group shares are trading lower after the company announced its merger with DiamiR Biosciences is expected to close on or about July 20, alongside a 1-to-10 reverse stock split.

Aptorum Group Announces 1-For-10 Reverse Stock Split, Effective July 20; Proposed Merger With DiamiR Biosciences Anticipated To Close Around July 20

Aptorum Group Limited, a Cayman Islands exempted company with limited liability (NASDAQ: APM) ("Aptorum Group" or "Aptorum" or "Company"), a clinical stage biopharmaceutical company dedicated to